Dr. Anthony Fauci Shares Insights on His Career and Leadership of the NIAID
Article Sidebar
Main Article Content
Abstract
In this interview, Dr. Anthony Fauci, who was until recently the director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, discusses the national response to the HIV/AIDS pandemic. He was the principal architect of the President's Emergency Plan for AIDS Relief, known as PEPFAR, that has saved millions of lives throughout the developing world by assuring access to life-saving antiretroviral therapies. In recent years, he's been the voice of our national response to SARS, Ebola, and COVID, and throughout this time, Dr. Fauci has led a large basic and translational immunology research laboratory, The Laboratory of Immunoregulation, which has revealed a trove of insights about HIV pathogenesis.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. Centers for Disease C. Pneumocystis pneumonia—Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250-2. PubMed PMID: 6265753.
2. Centers for Disease C. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30(25):305-8. PubMed PMID: 6789108.
3. Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, Gill K, Harkoo I, Jaggernath M, Kigozi G, Kiwanuka N, Kotze P, Lebina L, Louw CE, Malahleha M, Manentsa M, Mansoor LE, Moodley D, Naicker V, Naidoo L, Naidoo M, Nair G, Ndlovu N, Palanee-Phillips T, Panchia R, Pillay S, Potloane D, Selepe P, Singh N, Singh Y, Spooner E, Ward AM, Zwane Z, Ebrahimi R, Zhao Y, Kintu A, Deaton C, Carter CC, Baeten JM, Matovu Kiweewa F, Team PS. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024. doi: 10.1056/NEJMoa2407001. PubMed PMID: 39046157.
DOI: https://doi.org/10.1056/NEJMoa24070014. Greenspan NS. Design Challenges for HIV-1 Vaccines Based on Humoral Immunity. Front Immunol. 2014;5:335. doi: 10.3389/fimmu.2014.00335. PubMed PMID: 25076950; PMCID: PMC4099939.
DOI: https://doi.org/10.3389/fimmu.2014.003355. Collins F. We Are Squandering One of the Most Important Medical Advances of the 21st Century. New York Times. 2023 November 28, 2023.
6. Kariko K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165-75. doi: 10.1016/j.immuni.2005.06.008. PubMed PMID: 16111635.
DOI: https://doi.org/10.1016/j.immuni.2005.06.0087. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. doi: 10.1126/science.abb2507. PubMed PMID: 32075877; PMCID: PMC7164637.
DOI: https://doi.org/10.1126/science.abb25078. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, Cottrell CA, Becker MM, Wang L, Shi W, Kong WP, Andres EL, Kettenbach AN, Denison MR, Chappell JD, Graham BS, Ward AB, McLellan JS. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017;114(35):E7348-E57. doi: 10.1073/pnas.1707304114. PubMed PMID: 28807998; PMCID: PMC5584442.
DOI: https://doi.org/10.1073/pnas.17073041149. Morens DM, Folkers GK, Fauci AS. The Concept of Classical Herd Immunity May Not Apply to COVID-19. J Infect Dis. 2022;226(2):195-8. doi: 10.1093/infdis/jiac109. PubMed PMID: 35356987; PMCID: PMC9129114.
DOI: https://doi.org/10.1093/infdis/jiac10910. Greenhalgh T, MacIntyre CR, Baker MG, Bhattacharjee S, Chughtai AA, Fisman D, Kunasekaran M, Kvalsvig A, Lupton D, Oliver M, Tawfiq E, Ungrin M, Vipond J. Masks and respirators for prevention of respiratory infections: a state of the science review. Clin Microbiol Rev. 2024;37(2):e0012423. doi: 10.1128/cmr.00124-23. PubMed PMID: 38775460; PMCID: PMC11326136.
DOI: https://doi.org/10.1128/cmr.00124-2311. Dominik Guss C, Boyd L, Perniciaro K, Free DC, Free JR, Teresa Tuason M. The politics of COVID-19: Differences between U.S. red and blue states in COVID-19 regulations and deaths. Health Policy Open. 2023;5:100107. doi: 10.1016/j.hpopen.2023.100107. PubMed PMID: 38034472; PMCID: PMC10684792.
DOI: https://doi.org/10.1016/j.hpopen.2023.10010712. Saville M, Cramer JP, Downham M, Hacker A, Lurie N, Van der Veken L, Whelan M, Hatchett R. Delivering Pandemic Vaccines in 100 Days - What Will It Take? N Engl J Med. 2022;387(2):e3. doi: 10.1056/NEJMp2202669. PubMed PMID: 35249271.
DOI: https://doi.org/10.1056/NEJMp220266913. Cassetti MC, Pierson TC, Patterson LJ, Bok K, DeRocco AJ, Deschamps AM, Graham BS, Erbelding EJ, Fauci AS. Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness. J Infect Dis. 2023;227(12):1433-41. doi: 10.1093/infdis/jiac296. PubMed PMID: 35876700; PMCID: PMC9384504.
DOI: https://doi.org/10.1093/infdis/jiac29614. Abizadeh A. Academic journals are a lucrative scam – and we’re determined to change that: The Guardian; 2024 [updated July 16, 2024August 2024]. Available from: https://www.theguardian.com/commentisfree/article/2024/jul/16/academic-journal-publishers-universities-price-subscriptions.